.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,737,043

« Back to Dashboard

Details for Patent: 6,737,043

Title: Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
Abstract:The present invention relates to the delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route. Specifically, it relates to aerosols containing alprazolam, estazolam, midazolam or triazolam that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of alprazolam, estazolam, midazolam or triazolam. In a method aspect of the present invention, alprazolam, estazolam, midazolam or triazolam is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of alprazolam, estazolam, midazolam or triazolam, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering alprazolam, estazolam, midazolam or triazolam through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of alprazolam, estazolam, midazolam or triazolam; and, b) a device that forms an alprazolam, estazolam, midazolam or triazolam containing aerosol from the composition, for inhalation by the mammal.
Inventor(s): Rabinowitz; Joshua D. (Mountain View, CA), Zaffaroni; Alejandro C. (Atherton, CA)
Assignee: Alexza Molecula Delivery Corporation (Palo Alto, CA)
Filing Date:May 22, 2002
Application Number:10/155,373
Claims:1. A composition for delivery of a therapeutic compound, comprising a condensation aerosol a) formed by volatilizing a therapeutic compound selected from the group consisting of alprazolam, estazolam, midazolam or triazolam under conditions effective to produce a heated vapor of the compound, and condensing the heated vapor of the compound to form condensation aerosol particles, and b) characterized by less than 5% compound degradation products, and c) aerosol MMAD is less than 3 .mu.m.

2. The composition according to claim 1, wherein the condensation aerosol particles are characterized by less than 2.5 percent by weight of alprazolnm, estazolam, midazolam or triazolam degradation products.

3. The composition according to claim 1, wherein the condensation aerosol particles comprise at least 90 percent by weight of alprazolam, estazolam, midazolam or triazolam.

4. The composition according to claim 1, wherein the condensation aerosol particles comprise at least 95 percent by weight of alprazolam, estazolam, midazolam or triazolam.

5. A method of producing the therapeutic compound alprazolam, estazolam, midazolam or triazolam in an aerosol form comprising: a) volatilizing a therapeutic compound selected from the group consisting of alprazolam, estazolam, midazolam or triazolam under conditions effective to produce a heated vapor of the compound, and b) during said volatilizing, passing air through the heated vapor to produce aerosol particles of the compound comprising less than 5% compound degradation products and c) aerosol MMAD is less than 3 .mu.m.

6. The method according to claim 5, wherein the aerosol particles are formed at a rate of greater than 0.5 mg/sec.

7. The method according to claim 5, wherein said volatilizing includes heating a coating of the therapeutic compound, which is formed on a solid support having the surface texture of a metal foil, to a temperature sufficient to volatilize the compound from the coating.

8. The method according to claim 5, wherein the aerosol particles comprise less than 2.5 percent by weight of alprazolam, estazolam, midazolam or triazolam degradation products.

9. The method according to claim 7, wherein the coating of the compound on said solid support surface has a thickness between 0.2 and 4.8 microns.

10. The method according to claim 5, wherein the aerosol particles comprise at least 95 percent by weight of alprazolam, estazolam, midazolam or triazolam.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc